Principal Financial Group Inc Morphic Holding, Inc. Transaction History

Principal Financial Group Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 29, 2024	BUY	$26.64 - $40.31 $9,297 - $14,068	349 Added 3.68%	9,822 $345,000
Q4 2023 Feb 07, 2024	BUY	$19.95 - $31.0 $5,206 - $8,091	261 Added 2.83%	9,473 $273,000
Q3 2023 Nov 02, 2023	BUY	$21.33 - $59.42 $9,043 - $25,194	424 Added 4.82%	9,212 $211,000
Q2 2023 Aug 07, 2023	BUY	$34.33 - $62.11 $1,785 - $3,229	52 Added 0.6%	8,788 $503,000
Q1 2023 May 09, 2023	SELL	$26.01 - $48.69 $6,294 - $11,782	-242 Reduced 2.7%	8,736 $328,000
Q4 2022 Feb 09, 2023	BUY	$24.14 - $30.37 $25,757 - $32,404	1,067 Added 13.49%	8,978 $240,000
Q3 2022 Nov 09, 2022	BUY	$22.23 - $33.37 $175,861 - $263,990	7,911 New	7,911 $223,000
Q1 2022 May 09, 2022	SELL	$36.25 - $52.02 $157,941 - $226,651	-4,357 Closed	0 $0
Q4 2021 Feb 09, 2022	SELL	$43.27 - $65.72 $309,596 - $470,226	-7,155 Reduced 62.15%	4,357 $206,000
Q3 2021 Nov 09, 2021	BUY	$53.61 - $67.5 $171,230 - $215,595	3,194 Added 38.4%	11,512 $652,000
Q2 2021 Aug 10, 2021	BUY	$45.13 - $64.99 $375,391 - $540,586	8,318 New	8,318 $477,000

140

38.7M

4.2K

200K

Ticker MORF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,477,100
Market Cap $2.19B
Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.